Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Itacitinib in Moderate to Severe Ulcerative Colitis
2018-004491-35Phase 2Terminated
- Sponsor
- Incyte
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of itacitinib in autoimmune colitis (3 arms), sponsored by Incyte. Primary endpoint: Clinical Response at Week 12. Started Jul 2019; status: terminated.
02
Drugs
itacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-004491-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004491-35.